 Immunization high-risk infants months age split-product influenza vaccine Influenza important cause serious illness young children cardiopulmonary disease study centers immunogenicity safety influenza split-product vaccine children months bronchopulmonary dysplasia congenital heart disease total children children months age children months age Sera first second immunization weeks second immunization hemagglutination inhibition protection Ninety-five children adverse reactions Seroresponses age antigen specific responses ages A/Mississippi Children months age seroresponses A/Leningrad B/Victoria children months age Seroconversion rates antigens low children experienced adverse reactions immunologic mechanisms responsible serious influenzal disease effective immunization strategies young high-risk children